知镜 Cognispect · 医学文献与研究工作台

Effects of exogenous relaxin on dry eye in an experimental Sjögren's disease (SS) mouse model.

Carvalho LN, Wakamatsu TH, Gil CD, Gasparetto GB, Nasare AM, de Oliveira E, Rosa LR, Cristovam PC, Gomes JAP.
Experimental eye research · 2026-10-12 · PMID 42863741

文献摘要

Purpose To evaluate the potential of exogenous relaxin (RLX) as a treatment for dry eye disease (DED) in an experimental animal model of Sjögren's disease (SS). Methods Nonobese diabetic female (NOD) mice with SS-associated DED received RLX-based or vehicle eye drops (100 ng/mL) four times daily for 30 days. Clinical evaluations included measurements of tear production, assessment of keratitis, and histological analysis of the exorbital lacrimal gland. Inflammatory cytokine expression was measured using PCR. Results RLX-treated mice showed significant improvement in tear production and keratitis reversal. Qualitative histological analysis suggested better preservation of lacrimal gland architecture, with more evident acinar and ductal structures in the RLX-treated group. PCR analysis demonstrated reduced inflammatory cytokine expression (IL-1β, IL-6, IL-12a, IL-17a, TNFα, and IFNγ), and increased expression of RLX and its receptor RXFP1 in the RLX-treated group. Conclusions Exogenous relaxin shows therapeutic potential for DED in SS, demonstrated by clinical improvements and reduced inflammatory markers in an animal model of SS.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。